Thomas Scanlon

Title: Thomas Scanlon: Innovator in Adeno-Associated Virus Affinity Agents

Introduction

Thomas Scanlon is a notable inventor based in Lebanon, NH (US). He has made significant contributions to the field of biotechnology, particularly in the development of affinity agents for adeno-associated viruses. His work is essential for advancements in viral research and therapeutic applications.

Latest Patents

Thomas Scanlon holds 1 patent related to his innovative work. His patent, titled "AAV9 affinity agents," provides detailed information about affinity agents that comprise ligands specifically designed to bind adeno-associated viruses. These agents are crucial for the binding, isolation, and purification of adeno-associated viruses. The patent also discloses amino acid sequences of binding motifs or polypeptides included in the ligands, along with methods for creating these affinity agents.

Career Highlights

Throughout his career, Thomas has been associated with Avitide LLC, a company focused on bioprocessing solutions. His expertise in the field has allowed him to contribute significantly to the company's research and development efforts. His innovative approach has positioned him as a key player in the biotechnology sector.

Collaborations

Thomas Scanlon has collaborated with notable colleagues, including William Scott Dodson and Brandon Kier. These partnerships have fostered a collaborative environment that enhances the research and development of new biotechnological solutions.

Conclusion

In summary, Thomas Scanlon is a distinguished inventor whose work on adeno-associated virus affinity agents has made a significant impact in biotechnology. His contributions continue to influence the field and pave the way for future innovations.